Yaogeng Wang, R. Sparidans, Wenlong Li
Feb 22, 2020
Citations
1
Influential Citations
13
Citations
Quality indicators
Journal
British Journal of Pharmacology
Abstract
Larotrectinib is a FDA‐approved oral small‐molecule inhibitor for treatment of neurotrophic tropomyosin receptor kinase fusion‐positive cancer. We here investigated the functions of the multidrug efflux transporters ABCB1 and ABCG2, the SLCO1A/1B (OATP1A/1B) uptake transporters, and the multispecific drug‐metabolizing enzyme CYP3A in larotrectinib pharmacokinetic behaviour.